Jacobi Medical Center

Summary

Jacobi Medical Center is a medical facility located in Bronx, New York. This center is recognized for care of HIV Infection, Human Immunodeficiency Virus Infection, AIDS, Sickle Cell Disease, HIV/AIDS and other specialties. Jacobi Medical Center is involved with conducting 169 clinical trials across 235 conditions. There are 4 research doctors associated with this hospital, such as Kenneth Rivlin, MD, Abhishek Kumar, MD, Michael Rosenberg, MD, and Susan Gennaro, PhD.

Top PIs

Clinical Trials running at Jacobi Medical Center

Sickle Cell Disease

Solid Tumors

Thalassemia

Broken Bones

COVID-19

Heart Attack

Cardiovascular Risk

Diabetes

Type 1 Diabetes

HIV Infection

Etavopivat

for Sickle Cell Anemia

Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking into how safe treatment with etavopivat is and how well it works over a long period of time. The study will last for up to 264 weeks, but it will end earlier if etavopivat is approved in the participant's country.

Recruiting

2 awards

Phase 3

FTX-6058

for Sickle Cell Disease

This is a study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of Pociredir in participants with sickle cell disease.

Recruiting

1 award

Phase 1

Etavopivat

for Sickle Cell Disease

This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can reduce the damage to different organs, improve your exercise tolerance and reduce fatigue in people with sickle cell disease.The participants will either get etavopivat or placebo. Which treatment the participants will get is decided by chance. Etavopivat is a new medicine and is currently being tested in other studies in addition to this one. The study will last for about 2 years.

Recruiting

1 award

Phase 3

3 criteria